Clinical trials: Metastatic Liver Cancer
Colorectal Cancer
A Study of Bevacizumab and Modified FOLFOX-6 (mFOLFOX-6) in Participants With Metastatic Colorectal Cancer
The multicenter, open-label, single-arm, non-randomized, two-stage Simon's design, phase II study (The CLMO-001 Trial) will evaluate the efficacy and safety of bevacizumab in combination with mFOLFOX-6 (Levofolinic acid…
- Trial name
- NCT01383707
- Testing
- 5-Fluorouracil (5-FU), Bevacizumab, Levofolinic acid
- Where
- 11 sites in Italy
- Volunteers
- 77 people
- Sponsor
- Hoffmann-La Roche
Metastatic Distal Bile Duct Adenocarcinoma, Metastatic Gallbladder Carcinoma
Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer
This phase II trial investigates the effect of combining two immune therapies, atezolizumab and CDX-1127 (varlilumab), with or without cobimetinib, in treating patients with biliary tract cancer that cannot be removed by surgery…
- Conditions
- Metastatic Distal Bile Duct Adenocarcinoma, Metastatic Gallbladder Carcinoma, Metastatic Intrahepatic Cholangiocarcinoma, Recurrent Distal Bile Duct Adenocarcinoma
- Trial name
- NCT04941287
- Testing
- Atezolizumab, Biopsy, Biospecimen Collection
- Where
- 29 sites in United States
- Volunteers
- 57 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Neuroendocrine Tumor With Liver Metastases
Lenvatinib Plus Chemotherapy for pNET Liver Metastases
This prospective, non-randomized, concurrent parallel-controlled study will evaluate treatment response and resistance mechanisms in patients with pancreatic neuroendocrine tumors with liver metastases (pNET-LM) receiving…
- Trial name
- LEN-pNET (NCT07835893)
- Testing
- Lenvatinib, Chemotherapy
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Peking Union Medical College Hospital
Colorectal Liver Metastases
Folfox-B Study for Patients With Colorectal Liver Metastases
Objective: To evaluate the efficacy of the use of the combination of oxaliplatin, 5-fluorouracil, leucovorin and bevacizumab (FOLFOX-B) in patients with unresectable colorectal liver metastases, with the objective to downstage…
- Trial name
- NCT00508872
- Testing
- 5-Fluorouracil, Bevacizumab, Leucovorin
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- M.D. Anderson Cancer Center
Cholecystitis, Hepatocellular Carcinoma
Low Dose ICG for Biliary Tract and Tumor Imaging
Near-infrared fluorescence (NIRF) imaging after an intravenous injection of indocyanine green (ICG) allows for the intraoperative identification of liver anatomy.
- Conditions
- Cholecystitis, Hepatocellular Carcinoma, Liver Metastases
- Trial name
- ICG (NCT04942665)
- Testing
- Indocyanine green, PINPOINT Endoscopic Fluorescence
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Florida
Liver Cancer, Pancreatic Cancer
Phase II Trial Evaluating OS With Therasphere® + 2nd-Line FOLFOX in Pancreatic Liver Mets
The purpose of this study is to evaluate the safety and impact on survival with treatment with 90-Y glass microspheres in conjunction with leucovorin, 5-fluorouracil (5-FU) and oxaliplatin (FOLFOX) as second-line treatment with…
- Trial name
- NCT01581307
- Testing
- FOLFOX7 (Folinic acid, 5-Fluorouracil, and Oxaliplatin), TheraSpheres
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Colorectal Cancer, Metastatic Cancer
Chemotherapy Via an Implantable Pump Compared With a Subcutaneous Port for Unresectable Liver Metastases in Patients With Resected Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug or giving the drugs in different ways may kill more tumor cells.
- Trial name
- NCT00002793
- Testing
- fluorouracil, leucovorin calcium
- Where
- Germany
- Volunteers
- 336 people
- Sponsor
- Johann Wolfgang Goethe University Hospital
Chronic Disease, Neoplasm Metastasis
Facilitating Communication Study
This study is a randomized clinical trial of an intervention to improve outcomes for patients and their family by using ICU nurse facilitators to support, model, and teach communication strategies that enable patients and their…
- Conditions
- Chronic Disease, Neoplasm Metastasis, Lung Neoplasm, Pulmonary Disease, Chronic Obstructive
- Trial name
- FCS2 (NCT03721952)
- Testing
- Facilitator-Based Intervention
- Where
- 3 sites in United States
- Volunteers
- 977 people
- Sponsor
- University of Washington
Hepatocellular Carcinoma (HCC)
A Phase I Study of ERY974 in Patients With Hepatocellular Carcinoma
This is a multicenter, open-label, dose-escalation study designed to determine the maximum tolerated dose (MTD) by evaluating dose-limiting toxicities (DLTs) and to evaluate the safety, tolerability, pharmacokinetics, anti-tumor…
- Trial name
- NCT05022927
- Testing
- ERY974, Tocilicumab, Atezolizumab
- Where
- 11 sites in Japan, Taiwan
- Volunteers
- 179 people
- Sponsor
- Chugai Pharmaceutical
Liver Metastasis, Colon Cancer
EPA for Metastasis Trial 2
A significant proportion of patients who undergo liver surgery to remove bowel cancer that has spread to the liver (metastases) develop disease recurrence and die from the disease.
- Trial name
- EMT2 (NCT03428477)
- Testing
- Icosapent Ethyl
- Where
- 13 sites in United Kingdom
- Volunteers
- 418 people
- Sponsor
- Mark A Hull, PhD FRCP
Intrahepatic Cholangiocarcinoma (Icc)
Liquid Biopsy Using Exosomal miRNA Enables Risk Stratification of Potential Metastasis in Patients With Intrahepatic Cholangiocarcinoma.
Occult metastasis at the time of surgery is a major driver of poor outcomes in intrahepatic cholangiocarcinoma (ICC), yet reliable preoperative biomarkers to identify such patients are lacking.
- Trial name
- EXOMIC (NCT07224737)
- Testing
- EXOMIC small RNA sequencing, EXOMIC assay (qRT-PCR validation)
- Where
- United States
- Volunteers
- 230 people
- Sponsor
- City of Hope Medical Center
Colorectal Neoplasms, Liver Neoplasms
Neoadjuvant Colorectal Cancer With Unresectable Liver Metastases
The study was terminated early due to low enrollment with only 2 subjects enrolled and treated after being open for enrollment for over a year. Therefore, no meaningful efficacy analyses could be performed.
- Trial name
- NCT00106054
- Testing
- Combination therapy of irinotecan with 5-FU, leucovorin plus bevacizumab in the neoadjuvant setting.
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Pfizer
Colon Cancer Liver Metastasis, Inflammatory Response
Argipressin's Influence on Blood Loss During Hepatic Resection
Infusion of Argipressin during hepatic resection surgery may reduce blood loss. It may also reduce transfusion requirements, and mitigate the perioperative inflammatory response compared to placebo.
- Conditions
- Colon Cancer Liver Metastasis, Inflammatory Response, Vasopressin Causing Adverse Effects in Therapeutic Use
- Trial name
- ARG-01 (NCT05293041)
- Testing
- Argipressin
- Where
- Sweden
- Volunteers
- 248 people
- Sponsor
- Kristina Svennerholm
Colorectal Cancer Liver Metastases
PERIOPERATIVE TREATMENT WITH COI-B (CAPECITABINE, OXALIPLATIN, IRINOTECAN AND BEVACIZUMAB) OF HIGH RISK OR BORDERLINE RESECTABLE COLORECTAL CANCER LIVER METASTASES
Capecitabine, oxaliplatin, irinotecan and bevacizumab as perioperative strategy of borderline and/or high risk resectable colorectal cancer liver metastases
- Trial name
- COI-B (NCT02086656)
- Testing
- capecitabine, oxaliplatin, irinotecan and bevacizumab
- Where
- Italy
- Volunteers
- 46 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Liver Metastases of Colorectal Cancer
Chemotherapy Plus EGFR Monoclonal Antibody in Patients With Liver Metastases From Colorectal Cancer With ctDNA Superselective Negative Genes
The purpose of this Phase II single-arm study is to prospectively explore the efficacy of chemotherapy plus EGFR inhibitors in patients with liver metastases from total wild-type colorectal cancer with ctDNA superselective…
- Trial name
- NCT06490913
- Testing
- Capecitabine, oxaliplatin, Cetuximab
- Volunteers
- 33 people
- Sponsor
- Fujian Cancer Hospital
Liver Metastases, Mucinous Adenocarcinoma of the Colon
Cetuximab and/or Dasatinib in Patients With Colorectal Cancer and Liver Metastases That Can Be Removed by Surgery
This phase 0 trial is studying whether 2 weeks of cetuximab and dasatinib will change tumor cells in patients with colorectal cancer and liver metastases that can be removed by surgery.
- Conditions
- Liver Metastases, Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer
- Trial name
- NCT00835679
- Testing
- cetuximab, dasatinib, therapeutic conventional surgery
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer Metastatic
Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Colorectal Liver Metastasis
Microdevices have been used to ascertain in vivo drug response, which can lead to improved cancer treatment delivery; however, they have not been evaluated for liver tumors.
- Trial name
- NCT07193862
- Testing
- Doxorubicin, FOLFOX, Botensilimab, Balstilimab, Bevacizumab, FOLFIRI, FOLFIRINOX, AGEN2373
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Northwell Health
Colorectal Carcinoma, Hepatic Metastasis
Study With Dendritic Cell Immunotherapy in Resected Hepatic Metastasis of Colorectal Carcinoma
In this randomized multicentric phase II study, patients with colorectal carcinoma with resectable hepatic metastasis will be randomized to treatment with dendritic cells or to observation, following conventional treatment with…
- Trial name
- NCT01348256
- Testing
- Dendritic cells vaccine
- Where
- 2 sites in Spain
- Volunteers
- 58 people
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
Metastatic Colorectal Cancer
Yttrium-90 Radioembolization + Nivolumab for Liver + Extra-hepatic Metastases From Colorectal Cancer
This study has two portions. The main goal of the Phase Ib portion of this research study is to see at what time Yttrium-90 (Y-90) radioembolization therapy and nivolumab can safely be given to patients without having too many…
- Trial name
- NCT03307603
- Testing
- yttrium-90 radioembolization, Phase Ib - nivolumab, Phase II - nivolumab
- Sponsor
- Case Comprehensive Cancer Center
Liver Metastasis Colon Cancer
Selective Internal Radiation Therapy With 90Y Resin Micropheres for Refractory Colorectal Cancer Liver Metastases
Observational, feasibility study investigating biological aspects in patients with liver metastasis from colorectal cancer undergoing treatment with SIRT, by translational analysis of biological samples.
- Trial name
- SIRT (NCT04491929)
- Where
- Denmark
- Volunteers
- 30 people
- Sponsor
- Aarhus University Hospital